-
Science & technology
Science & technology
Novavax creates transformational vaccines that help address some of the world’s most pressing infectious diseases.
- Overview
- Our pipeline
- Matrix-M™ adjuvant
- Recombinant, protein-based nanoparticle vaccine
- Global vaccine approval/authorization map
COVID-19 UPDATESNovavax has demonstrated its ability to quickly produce viable vaccine candidates for emerging infectious diseases such as COVID-19.
-
Who we are
Who we are
We are a biotechnology company committed to help address serious infectious disease globally through the discovery, development, and delivery of innovative vaccines to patients around the world.
Build your future with usJoin other passionately curious people who are bringing innovative vaccines to the world
-
Insights
Insights
Novavax is committed to accelerating the development of new and promising vaccines by building on years of study and experience.

Marco Cacciuttolo
Senior Vice President,
Process and Analytical Development
Process and Analytical Development
Dr. Cacciuttolo is senior vice president of process and analytical development with responsibility for ensuring the quality and safety of Novavax’ vaccine candidates. He brings more than three decades of biochemical engineering experience to Novavax and has successfully developed commercial processes for many products.
Prior to joining Novavax in July 2020, Dr. Cacciuttolo served as head of manufacturing at Nosocomial Vaccine Corporation, chief operating officer at PathoVax LLC, and managing director of Batavia Biosciences. Earlier in his career, he held positions of increasing responsibility at MedImmune LLC, Medarex, Percivia LLC and Tetragenetics, Inc.
Dr. Cacciuttolo received a bachelor’s degree in biochemical engineering from Pontifical Catholic University of Valparaíso and a doctorate in biochemical engineering from the University of Maryland, Baltimore.